Biocon Gains Health Canada Nod for Denosumab Biosimilars
Toronto, Canada & Bengaluru, India, April 21, 2026 In a significant advancement for global biosimilars and bone health therapeutics,...
osteoporosis
Advertisement
Biocon Launches Denosumab Biosimilars in U.S.
BENGALURU, India & BRIDGEWATER, New Jersey, United States, April 7, 2026 Biocon Limited announced the U.S. commercial launch of...
Apotex Wins Approval for DENOZA Biosimilar in Canada
TORONTO, Ontario, Canada, April 7, 2026 Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved...
Teva Gains FDA Approval for PONLIMSI Biosimilar Drug
TEL AVIV, Israel & PARSIPPANY, N.J., USA, March 30, 2026 Teva Pharmaceutical Industries has received U.S. FDA approval for...
FDA Approves Accord BioPharma’s Denosumab Biosimilars, Expanding Access to Bone-Health Therapy
Durham, North Carolina, November 2025 Accord BioPharma has announced FDA approval of two denosumab biosimilars, OSVYRTI (denosumab-desu) and JUBEREQ...
Advertisements
FDA Grants Interchangeability for Celltrion’s Denosumab Biosimilars
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
FDA Approves Biosimilar Denosumab Expanding U.S. Patient Access
Budapest / London, September 29, 2025 Gedeon Richter and Hikma announced that the U.S. Food and Drug Administration (FDA)...
Advertisement
